Skip to main content

Table 2 Characteristics of 77 Crohn patients with pediatric-onset according to the Montreal classification regarding BMD adjusted for age

From: Age-of-onset-dependent influence of NOD2 gene variants on disease behaviour and treatment in Crohn’s disease

Pediatric-onset CD patients

Low BMD

Normal BMD

p-value

Z-score<−1

Z-score ≥−1

n=77

n=46

n=31

 

%

60%

40%

 

NOD2 variant n (%)

24 (52%)

10 (32%)

p=0.10

One variant allele

17

5

p=0.061

Two variant alleles

7

5

p=0.75

Homozygous variant alleles

7

0

p=0.037*

Gender: female/male in %

45/55

48/52

p=0.89

Age: y

   

mean/SD

25/12.8

24/13.9

p=0.62

median/interquartile range

21/17-30

19/15-29

p=0.29

average disease duration/SD

12.2/11.6

11.6/10.8

p=0.84

Age at diagnosis: y

   

mean/SD

13/3.6

12/5.1

p=0.33

median/interquartile range

14/11-16

13/10-17

p=0.69

Localization: n (%)

   

L1 ileal

8 (17%)

9 (29%)

p=0.27

L2 colonic

8 (17%)

6 (19%)

p=1.0

L3 ileocolonic

30 (65%)

16 (52%)

p=0.25

L4 isolated upper disease

0 (0%)

0 (0%)

p=1.0

Upper GI involvement

15 (33%)

13 (42%)

p=0.47

Behaviour: n (%)

   

B1 non-stricturing/penetrating

27 (59%)

20 (65%)

p=0.64

B2 stricturing

11 (23%)

6 (19%)

p=0.78

B3 penetrating intern

6 (13%)

3 (10%)

p=0.73

B3p penetrating perianal

9 (19%)

3 (10%)

p=0.34

Underweight at diagnosis

14/27 (52%)

5/22 (32%)

p=0.0453*

Underweight in 1y follow-up

14 (30%)

2 (6%)

p=0.0113*

Short stature

5 (11%)

1 (3%)

p=0.39

Treatment: n (%)

   

Steroid dependent/refractory

23 (50%)

9 (29%)

p=0.10

Azathioprine / MTX

35 (76%)

15 (48%)

p=0.016*

Anti-TNFα-antibody

20 (44%)

7 (26%)

p=0.09

  1. * indicates p value ≤ 0.05 considered to be significant.